The glycolytic rate in neurons is low in order to allow glucose to be metabolized through the pentosephosphate pathway (PPP), which regenerates NADPH to preserve the glutathione redox status and survival. This is controlled by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3), the pro-glycolytic enzyme that forms fructose-2,6-bisphosphate, a powerful allosteric activator of 6-phosphofructo-1-kinase. In neurons, PFKFB3 protein is physiologically inactive due to its proteasomal degradation. However, upon an excitotoxic stimuli, PFKFB3 becomes stabilized to activate glycolysis, thus hampering PPP mediated protection of redox status leading to neurodegeneration. Here, we show that selective inhibition of PFKFB3 activity by the small molecule AZ67 prevents the NADPH oxidation, redox stress and apoptotic cell death caused by the activation of glycolysis triggered upon excitotoxic and oxygen-glucose deprivation/reoxygenation models in mouse primary neurons. Furthermore, in vivo administration of AZ67 to mice significantly alleviated the motor discoordination and brain infarct injury in the middle carotid artery occlusion ischemia/reperfusion model. These results show that pharmacological inhibition of PFKFB3 is a suitable neuroprotective therapeutic strategy in excitotoxicrelated disorders such as stroke.
), and PFK158, an improved derivative of the widely used compound, 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one 1 (3PO) 19 . As shown in Fig. 1a ,b, both compounds (AZ67 and PFK158) were able to reduce the cellular levels of F2,6BP in a dose-dependent manner, with IC50 of 0.51 μM and 5.90 μM, respectively. Next, we investigated whether the reduction of cellular F2,6BP levels was a result of direct PFKFB3 inhibition. To do so, we used an enzymatic cell-free assay, which revealed that AZ67 inhibited the enzymatic activity of PFKFB3 with an IC50 of 0.018 µM (Fig. 1c) , a value that is in accordance with previously published results 18 . However, surprisingly, PFK158 had no effect on PFKFB3 enzymatic activity at any of the concentrations tested (up to 100 µM) (Fig. 1d) . Accordingly, although PFK158 is able to decrease F2,6BP (Fig. 1b) and glycolytic flux 20 , our data show that these effects are not due to PFKFB3 enzymatic inhibition. Since in this study we are focused specifically on PFKFB3 given its particular protein stability feature and potential impact on neurodegeneration, we did not consider PFK158 for further analyses.
AZ67 protects neurons against proteasome inhibition and ß-amyloid treatment. Since, in neurons, PFKFB3 is continuously degraded by the proteasome 7 , we reasoned that the stabilization of PFKFB3 caused by proteasomal inhibition may trigger neuronal apoptosis. As shown in Supplementary Fig. S1a , AZ67 lacks toxicity in the range 0.01-100 nM for 24 h in mouse cortical primary neurons. Incubation of neurons with MG132, a widely used proteasomal inhibitor, significantly increased neuronal apoptosis (Fig. S1a) , an effect that was dose-dependently counteracted by AZ67 (minimum effective dose, 1 nM; maximum effect at 10 nM), suggesting the involvement of PFKFB3 activity in MG132-mediated neuronal death. To investigate if AZ67 protects neurons from the toxicity caused by PFKFB3 stabilization upon a different kind of stimulus, we next used the amyloidogenic fragment 25-35 of the amyloid-ß peptide (Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] ), known to activate glutamate receptors 21 and to inhibit Cdh1 (ref. 22 ), i.e. conditions that stabilize PFKFB3 (ref. 13 ). Incubation of neurons with Aß 25-35 increased showing that the treatment of neurons with glutamate (100 µM; 10 mins), followed by washout, stabilized PFKFB3 protein levels after 24 h of incubation. Incubation of neurons with AZ67 (10 nM) for 24 h, after glutamate was removed, did not alter PFKFB3 protein levels. (b) Incubation of neurons with AZ67 for 24 h revealed no effect on lactate release. Treatment of neurons with NMDA (100 µM; 10 mins) or glutamate (100 µM; 10 mins), followed by washout, increased lactate released after 24 h of incubation (compare NMDA or glutamate versus none values at 0 nM AZ67). Incubation of neurons with AZ67 for 24 h, after NMDA or glutamate was removed, dose-dependently prevented the increase in lactate release. (c) Incubation of neurons with AZ67 for 24 h revealed no effect on F2,6BP concentrations. Treatment of neurons with NMDA (100 µM; 10 mins) or glutamate (100 µM; 10 mins), followed by washout, increased F2,6BP after 24 h of incubation. Incubation of neurons with AZ67 (10 nM) for 24 h, after NMDA or glutamate was removed, prevented the increase in lactate release. (d) Incubation of neurons with AZ67 for 24 h revealed no significant effect on the NADPH/NADP ratio. Treatment of neurons with NMDA (100 µM; 10 mins) or glutamate (100 µM; 10 mins), followed by washout, decreased the NADPH/NADP ratio after 24 h of incubation. Incubation of neurons with AZ67 (10 nM) for 24 h, after NMDA or glutamate was removed, prevented the decreased NADPH/ NADP ratio. (e) Incubation of neurons with AZ67 for 24 h revealed no effect on mitochondrial ROS. Treatment of neurons with NMDA (100 µM; 10 mins) or glutamate (100 µM; 10 mins), followed by washout, increased mitochondrial ROS after 24 h of incubation (compare NMDA or glutamate versus none values at 0 nM AZ67). Incubation of neurons with AZ67 for 24 h, after NMDA or glutamate was removed, dose-dependently prevented the increase in mitochondrial ROS. (f) Treatment of neurons with NMDA (100 µM; 10 mins) or glutamate (100 µM; 10 mins), followed by washout, triggered apoptotic death after 24 h of incubation (compare NMDA or glutamate versus none values at 0 nM AZ67). Incubation of neurons with AZ67 for 24 h, after NMDA or glutamate was removed, dose-dependently prevented apoptotic death up to 10 nM, AZ67; at concentrations of 100 nM to 10 µM, AZ67 showed progressive loss of protection. (g) Transfection of primary neurons with Pfk1-M (4 µg of DNA plasmid) efficiently increased PFK1-M protein levels. (h) Treatment of neurons with glutamate (100 µM; 10 mins), followed by washout, triggered apoptotic death after 24 h of incubation. Incubation of neurons with AZ67 (10 nM) for 24 h, after glutamate was removed, prevented apoptotic death. However, AZ67-mediated protection of apoptotic death was abolished when neurons were previously transfected with the fulllength cDNA coding for PFK1-M. Apoptosis was analysed only in the efficiently-transfected, GFP + neurons. (i) Treatment of neurons with NMDA (100 µM; 10 mins), followed by washout, triggered apoptotic death after AZ67 prevents glycolytic activation and redox stress upon excitotoxic stimuli in primary neurons. To test the ability of AZ67 to protect against the damage caused by an excitotoxic stimuli, neurons were subjected to a short-term incubation with glutamate (100 µM for 10 minutes) followed by a 24 h incubation in glutamate-free culture medium, a widely-used excitotoxic protocol 23 . In good agreement with our previous observations 13 , this treatment triggered PFKFB3 protein stabilization (Figs 2a and S1b) and activated glycolysis, as judged by the increase in the release of the glycolytic end-product, lactate, to the culture medium after 24 h of incubation (Fig. 2b) . Interestingly, the increased release of lactate was mimicked by treating neurons with the selective glutamate receptor agonist, N-methyl-D-aspartate (NMDA) (Fig. 2b) , and was dose-dependently abrogated by incubation of neurons with AZ67 immediately after the excitotoxic stimuli during 24 h (Fig. 2b) . The minimum concentration of AZ67 that showed to be fully efficient at preventing the increase in lactate release was 1 nM, although at 10 nM, AZ67 was maximally effective in the glutamate-mediated stimulus (Fig. 2b) . In good consistency with PFKFB3 protein stabilization 13 ( Fig. 2a) , treatment of neurons with the excitotoxic stimuli increased the levels of the PFKFB3 product, F2,6BP, by almost ~3-fold (Fig. 2c) , indicating increased PFKFB3 enzymatic activity. Notably, the increased F2,6BP levels were fully abolished by AZ67 at 10 nM (Fig. 2c ) without affecting PFKFB3 protein stability (Fig. 2a) . These data indicate that the pharmacological inhibition of PFKFB3 activity in neurons is sufficient to prevent excitotoxic stimuli-mediated activation of glycolysis. In contrast to neurons, astrocytes normally express high levels of PFKFB3 that are responsible for the high glycolytic phenotype of these glial cells 4, 7 . Moreover, by activating PFKFB3, glycolysis further increases in astrocytes upon inhibition of mitochondrial cytochrome c oxidase with nitric oxide 3, 4 . However, AZ67, at the low dose (10 nM) that is able to inhibit PFKFB3 activity in neurons (Fig. 2b) , did not inhibit basal or nitric oxide-stimulated glycolysis in astrocytes (Fig. S1c) . Since an increase in glycolysis leads to the impairment in the ability of neurons to regenerate NADPH through PPP activity 7 , we next assessed the redox state of this cofactor. As shown in Fig. 2d , stimulation of glutamate receptors triggered NADPH oxidation, a hallmark of PPP inhibition 7, 24 , as judged by the decreased NADPH/NADP ratio, an effect that was abrogated by incubating neurons with AZ67 (10 nM). Given that PPP-mediated regeneration of oxidized NADPH is essential for preventing the redox stress in neurons 7, 13 that accompanies mitochondrial damage in several neurodegenerative diseases 25, 26 , we next investigated mitochondrial reactive oxygen species (ROS). In good agreement with this notion, treatment of neurons with the excitotoxic stimuli promoted an increase in mitochondrial ROS (Fig. 2e) , and this effect was abolished by AZ67 (10 nM) (Fig. 2e) . Thus, inhibition of PFKFB3 activity upon an excitotoxic stimuli prevents the aberrant activation of glycolysis in neurons that leads to redox stress.
The neuroprotective effect of AZ67 against excitotoxicity is lost by genetically hampering glycolytic inhibition. Next, we aimed to further confirm whether AZ67, by preventing the activation of glycolysis in neurons, could account for the neuronal death associated with the excitotoxic stimuli. To do so, neurons were incubated with glutamate or NMDA, as above, and apoptosis assessed by annexin V +
/7AAD
− staining using flow cytometry. As shown in Fig. 2f , both types of excitotoxic stimuli significantly increased apoptotic neuronal death. Notably, this effect was dose-dependently prevented by AZ67, being 1 nM the minimum effective concentration and 10 nM the maximum dose showing protection (Fig. 2f) . A progressive loss of protection was observed at AZ67 concentrations ≥100 nM (Fig. 2f) . To address whether the neuronal protection exerted by AZ67 was a consequence of preventing the glycolytic activation, we assessed whether overexpression of the glycolytic enzyme, PFK1-muscle isoform, was able to rescue AZ67-mediated neuroprotection. We focused on the muscle PFK1 isoform (PFK1-M) given its very low sensitivity to F2,6BP allosteric activation 27 and, hence, its independence on PFKFB3 levels to fully activate glycolysis 28 . Accordingly, neurons were first transfected with the full-length cDNA encoding for PFK1-M (Figs 2g and S1d), and then subjected to the excitotoxic insults. As shown in Fig. 2h ,i, PFK1-M over-expression was able to abrogate the neuroprotection caused by AZ67 (10 nM) against glutamate or NMDA-mediated neuronal apoptosis. These results confirm that the neuroprotection exerted by AZ67 is a consequence of its ability to prevent glycolytic activation.
AZ67 prevents the metabolic switch from PPP to glycolysis, redox and mitochondrial stress, and apoptosis in an in vitro model of ischemia/reperfusion in primary neurons. Next, we aimed to elucidate whether AZ67 is able to prevent the metabolic switch and loss of survival triggered by a different type of excitotoxic stimulus in neurons. Given that neuronal damage associated with the loss of oxygen and nutrient supply is known to take place through an excitotoxic pathway 29, 30 , we prompted to investigate the potential beneficial effect of AZ67 in the in vitro model of oxygen and glucose deprivation (OGD) 31 . To do so, primary neurons were subjected to a 3 hours OGD incubation followed by a 4 hours reoxygenation (plus glucose) incubation period, a 24 h of incubation. Incubation of neurons with AZ67 (10 nM) for 24 h, after NMDA was removed, prevented apoptotic death. However, AZ67-mediated protection of apoptotic death was abolished when neurons were previously transfected with the full-length cDNA coding for PFK1-M. Apoptosis was analysed only in the efficiently-transfected, GFP + neurons. In all cases, data are mean ± S.E.M. values for n = 3 independent culture preparations. #p < 0.05 versus none at 0 nM AZ67; *p < 0.05 versus the corresponding treatment at 0 nM AZ67 (ANOVA followed by the least significant difference multiple range test . In good consonance with the excitotoxic models, OGD/reoxygenation triggered PFKFB3 protein stabilization (Figs 3a and S1e) and activated glycolysis, as judged by the increase in the release of lactate to the culture medium at the end of the reoxygenation period (Fig. 3b) . Interestingly, the increased release of lactate was abrogated by incubation of neurons with AZ67 (10 nM) immediately after OGD, during the reoxygenation period (Fig. 3b) . Notably, the increased release of lactate was fully abolished by AZ67 (10 nM) (Fig. 3b ) without affecting PFKFB3 protein stability (Fig. 3a) . To further confirm the activation of glycolysis in the OGD/reperfusion model, we determined the rate of [3- 3 H]glucose conversion into 3 H 2 O, a bona fide measure of the glycolytic flux 7, 32 . Treatment of neurons with the OGD/reoxygenation protocol increased the glycolytic flux (Fig. 3c) . Since increased glycolysis impairs glucose metabolism through PPP in neurons 7 , we next assessed the rate of PPP flux using a radiometric approach based on determining the difference in the release of 14 CO 2 from neurons incubated with either [1- 14 C]glucose or [6-14 C]glucose 7 . As shown in Fig. 3d , OGD/reoxygenation triggered the inhibition of PPP flux. Interestingly, both the increase in glycolysis and the decrease in PPP were abrogated by incubating neurons with AZ67 (10 nM) (Fig. 3c,d ). Since PPP is essential to maintain the antioxidant status of neurons 7, 13 , we investigated ROS. Treatment of neurons with the OGD/reoxygenation protocol increased H 2 O 2 release from neurons ( Fig. 3e ) and mitochondrial ROS (Fig. 3f) , effects that were significantly attenuated by AZ67 (10 nM) (Fig. 3e,f) . These data indicate that OGD/reperfusion triggers a metabolic switch from PPP to glycolysis that is associated with redox stress, and that these effects are significantly prevented by AZ67. As expected, OGD/reoxygenation impaired mitochondrial intermediary metabolism as observed by the decreased oxidation of [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]pyruvate (Fig. 3g) , a measure of pyruvate dehydrogenase (PDH) activity. However, PDH activity was unaffected by AZ67, neither when added alone or in the OGD/reoxygenation model (Fig. 3g) . Altogether, these data strongly suggest that AZ67 primarily affects glucose transformation through glycolysis and, indirectly, PPP, without altering mitochondrial intermediary metabolism. Furthermore, OGD/reperfusion triggered a loss in the mitochondrial inner membrane potential (∆ψ m ) (Fig. 3h) , likely consequence of the associated redox stress-mediated damage of the mitochondrial respiratory chain [15] [16] [17] . Interestingly, in good agreement with the redox stress rescue exerted by AZ67 (Fig. 3e,f) , this compound significantly prevented the ∆ψ m loss caused by OGD/reperfusion (Fig. 3h) . To ascertain if AZ67 affected neuronal survival in the OGD/reperfusion model, we assessed caspase-3 activity as a measure of apoptosis. As shown in Fig. 3i , OGD/reperfusion increased neuronal apoptosis, an effect that was significantly rescued by AZ67 (10 nM).
In vivo AZ67 administration protects mice against the motor discoordination caused by a brain ischemia/reperfusion model. Finally, we aimed to investigate if AZ67 was able to exert neuroprotection in vivo. Since it is very well documented that brain injury in stroke occurs through an excitotoxic mechanism 29, 30 , we studied whether AZ67 protected against damage caused in a mouse model of stroke. To achieve this, we induced a transient ischemia (30 min) by occlusion of the middle carotid artery (MCAO model), followed by 24 h reperfusion as described by a well-established protocol 31, 33 . Twenty-four hours after the transient MCAO episode, mice were subjected to the rotarod test, which revealed a ~40% performance of motor coordination in the MCAO group when compared with the sham-operated animals treated with vehicle (Fig. 4a) . Following this analysis, animals were then subjected to neurological examination following the Bederson test 34 . As shown in Fig. 4b , the results revealed severe neurological impairment (score >3) by MCAO. Immediately after the Bederson test, mice were euthanized to determine the percentage of infarcted volume in the brain, which resulted to be ~43% in the MCAO group (0% in the vehicle, sham-operated animals) (Fig. 4c) . AZ67 (60 mg/kg of body weight), or vehicle, were administered intravenously through the jugular vein immediately after the ischemic episode, at the start of the reperfusion. AZ67 administration in the sham-operated animals showed no signs of neurological deficit (NNS = 0 both for vehicle and AZ67; Fig. 4a ), motor discoordination (Fig. 4b) or brain injury (Fig. 4c) after 24 h when compared with vehicle, sham-operated mice, indicating lack of AZ67 toxicity at the dose used. Although the use of only one dose of AZ67 might represent a study limitation, notably, AZ67 administration at the selected dose of 60 mg/kg of body weight significantly improved the neurological deficit (NNS = ~2) (Fig. 4a) , prevented the motor discoordination (~60% performance) (Fig. 4b) and decreased the infarcted brain volume to 27% (Fig. 4c). (10 nM) during the 4 h of reoxygenation significantly prevented the increase in mitochondrial ROS formation. (g) Incubation of neurons with AZ67 for 4 h revealed no effect on pyruvate dehydrogenase (PDH) activity, as assessed by the conversion of [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]pyruvate in 14 CO 2 . However, treatment of neurons with OGD (3 h) followed by reoxygenation (plus glucose) (4 h) decreased PDH activity that was not altered by incubation of neurons with AZ67 (10 nM) during the 4 h of reoxygenation. (h) Incubation of neurons with AZ67 for 4 h revealed no effect on mitochondrial membrane potential (∆ψ m ), as assessed by flow cytometry. However, treatment of neurons with OGD (3 h) followed by reoxygenation (plus glucose) (4 h) decreased ∆ψ m . Incubation of neurons with AZ67 (10 nM) during the 4 h of reoxygenation prevented the decreased ∆ψ m . (i) Incubation of neurons with AZ67 for 4 h revealed no effect on caspase-3 activity, a measure of apoptosis. However, treatment of neurons with OGD (3 h) followed by reoxygenation (plus glucose) (4 h) increased apoptosis. Incubation of neurons with AZ67 (10 nM) during the 4 h of reoxygenation prevented the increase in apoptosis. In all cases, data are mean ± S.E.M. values for n = 3 independent culture preparations. #p < 0.05 versus OGD at 0 nM AZ67; *p < 0.05 versus the corresponding normoxic condition (ANOVA followed by the least significant difference multiple range test). See also Supplementary Data 1 
Discussion
Here we show that pharmacological inhibition of PFKFB3 activity, by preventing glycolytic activation, protects neurons against excitotoxicity both in the NMDA and glutamate receptor activation models and in the oxygen-glucose deprivation/reperfusion model. Furthermore, PFKFB3 inhibition also showed brain damage protection in the MCAO ischemic/reperfusion model in vivo. To our knowledge, this is the first time showing that inhibition of glycolysis, by the use of a small-molecule compound, shows a beneficial effect in a neurological disease model. In cancer cells, several PFKFB3 inhibitors of different chemical classes have been reported to inhibit glycolysis, on which these cells rely for proliferation and survival [35] [36] [37] [38] [39] . Amongst these PFKFB3 inhibitors, 3PO and its derivative PFK158 have been reported to reduce the cellular levels of F2,6BP, inhibit glucose uptake and lactate production, thus facilitating apoptosis in cancer cells. However, on our hands, PFK158 is inactive as PFKFB3 inhibitor in a purified human recombinant PFKFB3 enzymatic assay, at least at concentrations up to 100 μM. Intriguingly, similar results were previously reported for 3PO 18, 39 . Whether these compounds inhibit glycolysis by interfering with a glycolytic target different to PFKFB3 remains to be elucidated. In contrast, AZ67 is a bona-fide PFKFB3 inhibitor 18 that, on our conditions, inhibited human recombinant PFKFB3 kinase activity at with an IC50 of 18 nM and decreased cellular F2,6BP production in A549 cells with an IC50 of 510 nM. When compared with astrocytes and other tissues, neurons are, by far, the type of cell showing the smallest PFKFB3 abundance, which is virtually absent 7 . In good agreement with this, we found that lower concentrations of AZ67 (in the 1-10 nM range) were sufficient to efficiently abrogate the enhancements in F2,6BP, glycolysis www.nature.com/scientificreports www.nature.com/scientificreports/ and apoptosis in neurons. However, AZ67 was unable to decrease basal glycolysis nor to rescue the increased glycolytic activation in astrocytes. In vivo administration of the PFKFB3 inhibitor in the MCAO model could, in principle, enter all cells of the organism to broadly inhibit PFFKFB3 activity. However, our data showing lack of effect of AZ67 in astrocytic glycolysis strongly supports the notion that neuronal glycolysis would be more sensitive than astrocytic to AZ67, which is in good agreement with the large difference in PFKFB3 abundance between neurons and astrocytes 7 . This feature can be advantageous when determining the specific administration doses for future pre-clinical trials.
The rationale for targeting PFKFB3 and glycolysis as a therapeutic strategy for neurodegeneration relies on the physiological regulation of PFKFB3 protein stability in neurons. Thus, PFKFB3 is continuously degraded by the proteasome to keep glycolysis low in healthy neurons; however, PFKFB3 becomes stabilized upon proteasomal inhibition, leading to increased glycolysis and decreased PPP, which ultimately causes redox stress and neuronal death 7 . In good agreement with this notion, our data show that PFKFB3 inhibition by AZ67 exerts neuroprotection after blocking the proteasome with MG132. Furthermore, AZ67 prevented the neuronal death triggered by the Alzheimer's disease-related peptide Aß 25-35 , known to promote the degradation of Cdh1, i.e. the APC/C-cofactor necessary for PFKFB3 ubiquitylation and proteasomal degradation 22 . In the neuronal models of excitotoxicity and OGD/reoxygenation, the increase in glycolysis was paralleled with NADPH oxidation and PPP inhibition, respectively. NADPH oxidation impairs glutathione regeneration thus causing redox stress 7, 24 , a feature that we have herein confirmed according to the increase mitochondrial ROS upon the excitotoxic and OGD/ reoxygenation insults. Interestingly, AZ67 was able to rescue the enhancement in glycolysis, PPP inhibition, NADPH oxidation and redox stress, supporting the notion that restoring the equilibrium between glycolysis and PPP is a suitable and efficient neuroprotective strategy. Importantly, the neuroprotection exerted by AZ67 was abolished by over-expressing PFK1-M, an enzyme that activates glycolysis independently on F2,6BP levels 27 . This result demonstrates that the neuroprotective effect of AZ67 is due to its ability to inhibit the increase in glycolysis.
Excitotoxicity is a hallmark of various neurodegenerative diseases including stroke. Moreover, there is both pre-clinical 40 and clinical 41 evidence that tissue plasminogen activator (tPA), the only approved drug treatment for acute ischemic stroke, despite its obvious benefits presents adverse effects in the brain, including excitotoxicity potentiation 42 . Although neuroprotective strategies have been focused on NMDA receptor antagonists, unfortunately none of them have been successful, likely because functional NMDA receptors are essential for the normal brain physiology. Our data showing that targeting downstream the NMDA receptors activation -such as neuronal glycolysis-, rather than the NMDA receptors themselves, shows neuroprotection strongly suggest that targeting PFKFB3 would be a suitable alternative strategy for the prevention of the deleterious effects of NMDA receptor overstimulation in stroke and related excitotoxicity-associated neurological disorders, such as, amongst others, traumatic brain injury, Alzheimer' or Parkinson' diseases. 
Methods

PFKFB3 Enzymatic assay.
Recombinant full length human PFKFB3 protein purified from Sf9 baculoviral system acquired from SignalChem (Cat. #P323-30G). ATP, fructose-6-phosphate (F6P and other chemicals were from Sigma-Aldrich. ADP detection system (ADP-Glo) was purchased from Promega. Inhibitors were synthesized as described by Boyd et al. 18 . The kinase activity of the PFKFB3 protein was detected by measuring production of ADP from ATP in the presence of F6P. The reactions were assembled in 384 well plates in a total volume of 25 µl. Test compounds were serially diluted in dimethyl sulfoxide (DMSO). Reactions were set up by mixing test compounds with the enzyme and pre-incubating for 15 min. ATP and F6P were next added to initiate the reactions. The final assay composition included: 100 mM Tris-HCl pH 8.0, 4 mM MgCl 2 , 5 mM KH 2 PO 4 , 5 mM DTT, 20 mM KF, 0.02% BSA, 1% DMSO (from the compounds), 15 nM enzyme, 20 µM ATP (Km = 16 µM) and 10 µM F6P (Km = 6 µM). We used a low concentration of PFKFB3 protein (15 nM) since concentrations higher than 50 nM showed to hydrolyze ATP in the absence of F6P. Thus, under the conditions used in our experiments, ADP formation was solely due to F6P phosphorylation by PFKFB3. The kinase reactions were allowed to proceed for 1 hour at room temperature. Aliquots of the reaction mixtures (5 µl) were transferred to fresh white 384 well plates and mixed with 5 µl of the ADP-Glo reagent, followed by incubation for 30 min. The luminescent kinase detection reagent was added (10 µl) and, following additional incubation for 15 min, the plates were read with a luminescence plate reader (Analyst HT). Positive (no enzyme; 100% inhibition) and negative (DMSO instead of AZ67 or PFK158; 0% inhibition) control samples were assembled in each assay plate and were used to calculate percent inhibition values of test compounds.
Fructose-2,6-bisphosphate determinations. For F2,6BP determinations, cells were lysed in 0.1 N NaOH and centrifuged (20,000 × g, 20 min ). An aliquot of the homogenate was used for protein determination, and the remaining sample was heated at 80 °C (5 min), centrifuged (20.000 × g, 20 min) and the resulting supernatant used for the determination of F2,6BP concentrations using the coupled enzymatic reaction and F2,6BP standards as described by Van Schaftingen www.nature.com/scientificreports www.nature.com/scientificreports/ atmosphere. At 72 hours after plating, medium was replaced using Neurobasal (Life Technologies) supplemented with 2 mM glutamine, 5 mM glucose, 0.25 mM pyruvate and 2% B27 supplement (Life Technologies) minus antioxidants (MAO; i.e., lacking vitamin E, vitamin E acetate, superoxide dismutase, catalase and glutathione). Six days after plating medium was replaced again. Cells were used at day 9. Primary cultures of brain cortical astrocytes were prepared from either C57BL/6 mice of 0-1 days-old neonates. Cell suspensions were seeded at 2. Cell transfections. Primary neurons were transfected with 1.6 µg/mL of a pIRES2-EGFP plasmid vector (Invitrogen) harbouring the full-length cDNA coding for the human muscle 6-phosphofructo-1-kinase muscle isoform (PFK1-M) 28 (accession number, NM_000289.1) using Lipofectamine LTX-PLUS Reagent (Life Technologies) according with manufacturer's protocol. Transfections were performed 24 hours before cells collection. Control cells were transfected with the empty vector.
Cell treatments. For NMDA receptors activation, neurons at 8 days in vitro were incubated with 100 μM glutamate (plus 10 μM glycine) or 100 μM NMDA (plus 10 μM glycine) for 10 minutes. Neurons were then washed and further incubated in culture medium with the PFKFB3 inhibitors for 24 hours. For amyloid-ß treatment, the active truncated amyloid-β peptide Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] (BioNova Cientifica S.L., Madrid, Spain) was used. Aß [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] was dissolved in distilled water at a concentration of 1 mg/ml and then incubated at 37 °C for 3 days to induce its oligomerization 44 . We have shown that Aß [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] exerts neurotoxicity following identical mechanism to the full-length Aβ 1-42 peptide 21 . Neurons were incubated in culture medium containing oligomerized Aβ 25-35 (10 µM) or the corresponding scramble non-aggregable peptide (Aβ ) (BioNova Cientifica S.L.), which was used as control. Neurons at 8 days in vitro were incubated with Aß [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] plus the PFKFB3 inhibitors for 24 hours. To inhibit the proteasome, neurons were incubated with MG132 (10 µM) for 2 hours. To inhibit cytochrome c oxidase activity, astrocytes at 14 days in vitro were incubated with the nitric oxide donor, DETA-NONOate (0.5 mM) 4 for 4 hours.
Oxygen and glucose deprivation (OGD)/reoxygenation protocol. After 8 days in culture, neurons
were subjected to oxygen and glucose deprivation (OGD) by incubating cells at 37 °C in an incubator equipped with an air lock and continuously gassed with 95% N 2 /5% CO 2 , for 3 hours. The incubation medium (Neurobasal medium without glucose) was previously gassed with 95% N 2 /5% CO 2 for 5 min. In parallel, neurons were incubated in Neurobasal complete medium (normoxia condition) at 37 °C in a humidified atmosphere of 95% air/5% CO 2 . After OGD, neurons were further incubated for 4 hours with (or not) AZ67 10 nM in Neurobasal medium at 37 °C in a humidified atmosphere of 95% air/5% CO 2 (reoxygenation after OGD) 31 .
Western blotting. Neurons were lysed in RIPA buffer (2% sodium dodecylsulphate, 2 mM EDTA, 2 mM EGTA and 50 mM Tris pH 7.5), supplemented with protease and phosphatase inhibitor cocktail (100 μM phenylmethylsulfonyl fluoride, 50 μg/ml antipapain, 50 μg/ml pepstatin, 50 μg/ml amastatin, 50 μg/ml leupeptin, 50 μg/ml bestatin, 1 mM o-vanadate, 50 mM NaF, and 50 μg/ml soybean trypsin inhibitor) and boiled for 5 min. Extracts were centrifuged at 13,000 × g for 5 min at 4 °C, and aliquots of lysates (50 μg protein, unless otherwise stated) were subjected to sodium dodecyl sulfate-polyacrylamide (SDS-PAGE) electrophoresis on a 8, 10 or 12% acrylamide gel (MiniProtean, Bio-Rad) including PageRuler Plus Prestained Protein Ladder (Thermo). The resolved proteins were transferred electrophoretically to nitrocellulose membranes (Hybond-ECL, Amersham Bioscience Europe GmbH, Barcelona, Spain). Membranes were blocked with 5% (w/v) low-fat milk in 20 mM Tris, 500 mM NaCl, and 0.1% (w/v) Tween 20, pH 7.5, for 1 h. After blocking, membranes were immunoblotted with primary antibodies at dilutions ranging from 1:500 to 1:40,000 overnight at 4 °C. After incubation with the secondary antibodies (all at 1:10,000 dilution), membranes were immediately incubated with the enhanced chemiluminescence kit WesternBright ECL (Advansta, Menlo Park, California, USA) for 2 min or SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Scientific, Offenbach, Germany) for 5 min, before exposure to Fuji Medical X-Ray film (Fujifilm), and the autoradiograms scanned. Biologically independent replicates were always performed ( Supplementary Fig. S5 ), and a representative western blot is shown.
Primary antibodies for western blotting. Immunoblotting was performed using mouse monoclonal anti-PFKFB3 (1:500) (H0005209-M08, Novus Biologicals), mouse monoclonal anti-glyceraldehyde dehydrogenase (GAPDH; 1:40,000) (AM4300, Ambion) and antiserum against muscle PFK1 isoform (PFK1-M; 1:10) 4 .
Secondary antibodies for western blotting. Immunoblotting was performed using horseradish peroxidase-conjugated goat anti-rabbit IgG and goat anti-mouse IgG (Santa Cruz Biotechnologies).
Mitochondrial ROS. Mitochondrial Supplementary Fig. S2 for the flow cytometry workflow for MitoSox).
